Mitochondrial uncouplers for modulating immune responses in cancer therapy

Overview

Mitochondrial uncouplers (MUs) present a promising avenue for modulating immune responses in cancer therapy. These compounds, currently under clinical trials for prostate and colon cancer, have shown potential to influence the immune environment by affecting inflammasome-mediated responses. The research aims to explore the role of MUs in enhancing CAR-T cell therapy, a treatment that modifies immune cells to better attack cancer cells. By altering the bioenergetics of immune cells, MUs may improve their efficiency and efficacy in targeting cancer cells.

Technical specifications

• MUs are known to impact aerobic glycolysis and oxidative phosphorylation (OXPHOS) in cancer cells.
• They exhibit immunomodulatory properties that can either inhibit or enhance inflammation based on the microenvironment and disease stage.
• The research will focus on the interaction of MUs with glucose uptake transporters (GLUT) and their effects on primary immune cells like T-cells and macrophages.
• The study will use pancreatic cancer cell models and inflammasome models to evaluate the impact on cellular bioenergetics and immune response.
• Key questions include the role of MUs in metabolic changes and protein inhibition, with a focus on compounds like niclosamide.

Technology readiness level

The research is at Technology Readiness Level 3, indicating experimental proof of concept. Future validation will include detailed studies on cellular functions, bioenergetics, and the potential therapeutic implications of MUs in cancer therapy.